Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Thu, 29/06/2017 - 07:30
Domainex expands partnership with Imperial College London to reduce heart muscle damage during heart attacks
Wed, 14/06/2017 - 07:30
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks.
Mon, 15/05/2017 - 10:00
London, UK, 15th May 2017 / Sciad Newswire / Orthonika Limited, a spin-out from Imperial College London, is pleased to ann
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Mon, 24/04/2017 - 07:30
Phase 2a RSV Challenge Study Planned for Q3 2017
- « first
- ‹ previous